Abstract:Objective:To study the value of BCSG1 on evaluating the curative effect of neoadjuvant chemotherapy (NC) for breast cancer.
Methods:The expression of BCSG1 in cancer tissue was assayed by immunohistochemistry and RTPCR in 36 cases of breast cancer patients before and after receiving NC of CEF (cyclophosphamide, epirubicin and fluorouracil) regimen. The therapeutic response of NC was evaluated by morphological and pathological observation. The relationship between expression of BCSG1 and morphological response to NC was analyzed.
Results:Among the studied cases, the diameter of tumor significantly decreased（P<0.01）and the improvment rate of the treatment effect (CR+PR) was 85.6%. The expression of BCSG1 mRNA （P<0.05）and the high expression rate of BCSG1（P<0.01）were decreased significantly after receiving NC than that before NC.
Conclusions:After NC,the expression of BCSG1 mRNA and protein was decreased significantly,which had negative relation to the therapeutic effect of NC. BCSG1 can be a prognosticate gene to evaluate the effect of NC in breast cancer patients.